NASDAQ
No company description is available yet.
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.
Where price sits today against its own history. A description, not a forecast.
Average return in each calendar month, Jun 30, 2026 to Sep 30, 2026. 1 years is 1 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
| Year | J | F | M | A | M | J | J | A | S | O | N | D | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0 | +0 | +5 | −0 | +5% |
Each year's monthly returns in %, the observations behind the averages. The last column compounds the year's months; a year the history only partly covers is faded.
The SPAC is successfully completing a business combination with a clinical-stage biotech company backed by substantial PIPE financing ($300M) from reputable healthcare investors. The deal provides clear strategic value with a late-stage obesity drug candidate (CX11) that has demonstrated positive Phase 2 results and FDA alignment on regulatory pathway, positioning the combined company for growth through 2029.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.